MA46844A - Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation - Google Patents

Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation

Info

Publication number
MA46844A
MA46844A MA046844A MA46844A MA46844A MA 46844 A MA46844 A MA 46844A MA 046844 A MA046844 A MA 046844A MA 46844 A MA46844 A MA 46844A MA 46844 A MA46844 A MA 46844A
Authority
MA
Morocco
Prior art keywords
antigen binding
binding proteins
use methods
gitr antigen
gitr
Prior art date
Application number
MA046844A
Other languages
English (en)
Inventor
Heather Brodkin
Daniel Hicklin
Sonja Kleffel
Nels P Nielson
Jose-Andres Salmeron-Garcia
Cynthia Seidel-Dugan
William Winston
Original Assignee
Potenza Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potenza Therapeutics Inc filed Critical Potenza Therapeutics Inc
Publication of MA46844A publication Critical patent/MA46844A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA046844A 2016-11-19 2017-11-19 Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation MA46844A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662497428P 2016-11-19 2016-11-19
US201762448644P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
MA46844A true MA46844A (fr) 2019-09-25

Family

ID=62146165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046844A MA46844A (fr) 2016-11-19 2017-11-19 Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation

Country Status (17)

Country Link
US (2) US10988545B2 (fr)
EP (1) EP3541845A1 (fr)
JP (1) JP7572147B2 (fr)
KR (1) KR102574071B1 (fr)
CN (1) CN110248960A (fr)
AU (1) AU2017362721A1 (fr)
BR (1) BR112019010128A2 (fr)
CO (1) CO2019006424A2 (fr)
IL (1) IL266720A (fr)
JO (1) JOP20190100A1 (fr)
MA (1) MA46844A (fr)
MX (1) MX2019005821A (fr)
PH (1) PH12019501108A1 (fr)
TW (1) TWI783953B (fr)
UA (1) UA126389C2 (fr)
WO (1) WO2018094300A1 (fr)
ZA (1) ZA201902939B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
US10994021B1 (en) * 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
EP4161655A2 (fr) 2020-06-08 2023-04-12 University of Washington Nanoparticules liées à un anticorps
EP4339209A4 (fr) * 2021-05-10 2025-05-28 MediMabbio Inc. Anticorps anti-gitr et leurs utilisations
EP4437112A1 (fr) * 2021-11-24 2024-10-02 Formycon AG Protéines de fusion ace2 améliorées
IL314907A (en) 2022-03-15 2024-10-01 Yeda Res & Dev Antibodies against GITR and their uses

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL97459A0 (en) 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
WO1993016177A1 (fr) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogeneisation de ciblages de genes
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1189379A1 (fr) 2000-09-14 2002-03-20 Alcatel Procédé et système d'amélioration de la capacité de canal pour une communication point-à-multipoint par un système radio
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002061071A2 (fr) 2000-12-18 2002-08-08 Dyax Corp. Banques ciblees de capsides genetiques
WO2003006058A1 (fr) 2001-07-12 2003-01-23 Wyeth Marqueurs differentiels cd25+ et leurs utilisations
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (fr) 2001-10-25 2012-12-04 Genentech, Inc. Compositions de glycoproteine
US6715202B2 (en) 2001-11-02 2004-04-06 American Standard International Inc. Tube bender for forming serpentine heat exchangers from spine fin tubing
US6579430B2 (en) 2001-11-02 2003-06-17 Innovative Technology Licensing, Llc Semiconductor wafer plating cathode assembly
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1498490A4 (fr) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Procede de production de composition anticorps
EP1500400A4 (fr) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Medicament contenant une composition anticorps
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004058183A2 (fr) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agents recepteurs beta de la lymphotoxine combine a des agents chimiotherapeutiques
US7618632B2 (en) * 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
WO2005007190A1 (fr) 2003-07-11 2005-01-27 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
WO2005007150A2 (fr) 2003-07-17 2005-01-27 Bar-Ilan University Methode et composition pharmaceutique permettant d'inhiber la synthese de proteines du sperme
US6864697B1 (en) 2003-08-06 2005-03-08 Taiwan Semiconductor Manufacturing Co. Ltd Flip-over alignment station for probe needle adjustment
US20050035586A1 (en) 2003-08-12 2005-02-17 Martin Samuel V. Magnetically pulse welded underbody
JP2005081663A (ja) 2003-09-08 2005-03-31 Nissan Motor Co Ltd 樹脂製チューブ及び燃料系配管用チューブ
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
CA2604032C (fr) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1955708A4 (fr) 2005-11-24 2013-02-06 Dainippon Sumitomo Pharma Co Nouveau potentialisateur d'induction de lymphocyte t cytotoxique a memoire
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
SG181893A1 (en) 2009-12-22 2012-08-30 Hoffmann La Roche Sequence dependent aggregation
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
EP2748202B1 (fr) * 2011-08-23 2018-07-04 Roche Glycart AG Molécules bispécifiques de liaison à un antigène
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HUE037720T2 (hu) 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
CN103217489B (zh) * 2013-01-15 2016-03-09 珠海市丽珠单抗生物技术有限公司 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法
UY35517A (es) * 2013-04-04 2014-10-31 Mabxience S A Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
HK1225740A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
JP6553042B2 (ja) * 2013-09-05 2019-07-31 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 変更されたグリコシル化パターンを有するＦｃ含有分子を産生する細胞並びにその方法及び使用
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
SI3148579T1 (sl) * 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
CN108883173B (zh) * 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法

Also Published As

Publication number Publication date
ZA201902939B (en) 2022-08-31
JOP20190100A1 (ar) 2019-05-01
EP3541845A1 (fr) 2019-09-25
CN110248960A (zh) 2019-09-17
PH12019501108A1 (en) 2019-07-29
BR112019010128A2 (pt) 2019-10-08
JP2019537449A (ja) 2019-12-26
KR102574071B1 (ko) 2023-09-06
TWI783953B (zh) 2022-11-21
WO2018094300A8 (fr) 2019-05-02
US10988545B2 (en) 2021-04-27
WO2018094300A1 (fr) 2018-05-24
US20210269542A1 (en) 2021-09-02
AU2017362721A1 (en) 2019-05-23
JP7572147B2 (ja) 2024-10-23
RU2019118800A (ru) 2020-12-21
IL266720A (en) 2019-07-31
TW201819416A (zh) 2018-06-01
KR20190095298A (ko) 2019-08-14
CO2019006424A2 (es) 2019-08-20
US20180208665A1 (en) 2018-07-26
UA126389C2 (uk) 2022-09-28
RU2019118800A3 (fr) 2021-03-23
MX2019005821A (es) 2019-10-07

Similar Documents

Publication Publication Date Title
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
EP3635013A4 (fr) Protéines de liaison à la nectine-4 et leurs procédés d'utilisation
EP3487887A4 (fr) Protéines de liaison aux antigènes multispécifiques et leurs procédés d'utilisation
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
EP3500594A4 (fr) Anticorps, fragments de liaison, et procédés d'utilisation
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3612218A4 (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3442574A4 (fr) Nouvelles molécules de liaison à b7-h3, leurs conjugués anticorps-médicaments et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3544629A4 (fr) Protéines trispécifiques ciblang le psma et procédés d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3328994A4 (fr) Protéines de liaison d'antigène ciblant cd56 et leurs utilisations
EP3802617A4 (fr) Protéines de liaison multi-spécifiques et procédés d'utilisation associés
MA46844A (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
EP3355920A4 (fr) Protéines de liaison à pd-1 et leurs méthodes d'utilisation